In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
Seventy strains of Clostridium difficile, all isolated from symptomatic patients, were found to be uniformly susceptible to ramoplanin, a new glycolipodepsipeptide antibiotic, and to four glycopeptides (vancomycin, teicoplanin, and two semisynthetic teicoplanin derivatives). Ramoplanin is recommended for further evaluation in the treatment of C. difficile-associated disease.
Biavasco
F
F
Institute of Microbiology, University of Ancona Medical School, Italy.
Manso
E
E
Varaldo
P E
PE
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects*; D047630:Depsipeptides; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D006020:Glycopeptides / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000494:pharmacology; D012310:Ristocetin / Q000031:analogs & derivatives; D017334:Teicoplanin / Q000031:analogs & derivatives; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D047630:Depsipeptides; D006020:Glycopeptides; D010456:Peptides, Cyclic; C041438:ramoplanin; C068029:MDL 62873; D012310:Ristocetin; D017334:Teicoplanin; D014640:Vancomycin; C063101:teicoplanin aglycone